The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b trial of duvelisib, a PI3K-δ,γ inhibitor, in combination with obinutuzumab in patients with CLL/SLL previously treated with a Bruton’s tyrosine kinase inhibitor (BTKi).
 
James Stewart Blachly
Research Funding - Infinity Pharmaceuticals
 
Jennifer R. Brown
Honoraria - Pharmacyclics
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Pharmacyclics; Sanofi
Research Funding - Celgene; Gilead Sciences; Pharmacyclics; Sanofi
 
Jacqueline Claudia Barrientos
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Janssen; Pharmacyclics
Research Funding - Abbvie; Gilead Sciences; Pharmacyclics
 
Nitin Jain
Honoraria - Novartis; Pharmacyclics
Consulting or Advisory Role - Novartis; Pharmacyclics
Research Funding - Bristol-Myers Squibb; Pfizer; Pharmacyclics; Seagen
 
Virginia Kelly
Employment - Infinity Pharmaceuticals; Takeda
Stock and Other Ownership Interests - Infinity Pharmaceuticals; Takeda
 
Stephanie Garnick
Employment - Infinity Pharmaceuticals
Stock and Other Ownership Interests - Infinity Pharmaceuticals
 
Jill Rodstrom
Employment - Infinity Pharmaceuticals
Stock and Other Ownership Interests - Infinity Pharmaceuticals
 
Jennifer Sweeney
Employment - Infinity Pharmaceuticals
Stock and Other Ownership Interests - Pfizer
 
Shijie Tang
Employment - Infinity Pharmaceuticals; Millennium; Novartis (I)
Stock and Other Ownership Interests - Infinity Pharmaceuticals; Novartis (I)
 
John C. Byrd
No Relationships to Disclose